Business
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit
Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and
About this update from Transcode Therapeutics, Inc.
[{"type":"text","content":"Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in Investors' section of the TransCode Therapeutics website.\n\n\n\n\n\nEvent:\n\n\nQ4 Investor Summit\n\n\n\n\n\nDate:\n\n\nNovember 16-17th, 2021\n\n\n\n\n\nPresentation:\n\n\nNovember 17th at 10:15AM ET\n\n\n\n\n\nLocation:\n\n\nhttps://us06web.zoom.us/webinar/register/WN_P1C4IlpCSEi4d5wjRmsVqA\n\n\n\n\n\n1x1s will be available for qualified investors\nThe conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration\nAn archived replay of TransCode Therapeutics presentation will be available immediately after the presentation via the Webcast link. The presentation will also live on the Investor Summit website for 90 days after the event.\n\nAbout TransCode Therapeutics\nTransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in Investors' section of the TransCode Therapeutics website.\nFor further information:\nTransCode Therapeutics, Inc.\nTom Fitzgerald, CFO\[email protected]\nAbout the Investor Summit\nThe Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising of institutional investors, family offices, and h...